Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Revell

Physician Assistant Southlake, TX Physician Assistant

NPI 1255777900 CMS profile 11112340

431 E State Highway 114 Ste 300, Southlake, TX 76092

Open in the dashboard

General payments

$9,086

491 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Revell of Southlake, TX is reported in the CMS Open Payments database as having received $9,086 across 491 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,419 136
2024 General $2,037 111
2023 General $1,792 85
2022 General $1,285 71
2021 General $1,554 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Revell
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Meredith Revell were reported at $2,419. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Meredith Revell Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,554 $132 $37–$438 $132
2022 $1,285 $155 $48–$522 $149
2023 $1,792 $167 $52–$557 $160
2024 $2,037 $178 $55–$600 $164
2025 $2,419 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,288 59 payments
  2. AbbVie, Inc. $966 56 payments
  3. Sun Pharmaceutical Industries Inc. $723 33 payments
  4. Incyte Corporation $584 25 payments
  5. E.R. Squibb & Sons, L.L.C. $488 23 payments
  6. Genzyme Corporation $472 22 payments
  7. Galderma Laboratories, L.P. $456 29 payments
  8. Novartis Pharmaceuticals Corporation $435 17 payments
  9. LEO Pharma Inc. $420 19 payments
  10. Amgen Inc. $415 29 payments
  11. Other $2,839 179 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,694 485 payments
  2. Education $393 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,141 49 payments
  2. DUPIXENT $685 32 payments
  3. OPZELURA $584 25 payments
  4. SOTYKTU $488 23 payments
  5. Otezla $415 29 payments
  6. SKYRIZI $396 24 payments
  7. SIMPONI ARIA $371 23 payments
  8. STELARA $371 23 payments
  9. SIMPONI $371 23 payments
  10. ADBRY $354 16 payments
  11. Other $5,427 323 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

210

Median for Physician Assistant: 241

Drug cost

$56,912

Median for Physician Assistant: $4,110

Branded share of claims

5.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 11 $53,192
Clobetasol Propionate Generic 19 $1,244
Ketoconazole Generic 50 $853
Doxycycline Hyclate Generic 23 $711
Triamcinolone Acetonide Generic 39 $309
Minoxidil Generic 22 $220
Nystatin Generic 18 $163
Spironolactone Generic 16 $159
Mupirocin Generic 12 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $303
$303 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $280
$280 — —
SKYRIZI
  • AbbVie, Inc. $205
$205 — —
VTAMA
  • Dermavant Sciences, Inc. $152
$152 — —
OPZELURA
  • Incyte Corporation $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

491 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record